Aehr is betting on silicon photonics to drive sustained growth, as customer ramp ups and new orders are expected to support 15-20% of fiscal 2027 revenues.

Cooling inflation and softer jobs data have eased Fed rate-hike fears, fueling a strong rally in select growth and AI stocks.

AEHR's $22M AI order underscores rising WLBI demand as chip complexity and costs increase, while backlog and bookings point to strong growth.

AEHR's 72.2% surge reflects record bookings, a $100.6M backlog and rising AI demand, but its premium valuation raises the stakes.

Aehr Test Systems (AEHR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Aehr Test Systems (AEHR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

The average of price targets set by Wall Street analysts indicates a potential upside of 49.6% in Aehr Test Systems (AEHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 49.6% in Aehr Test Systems (AEHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Aehr's record bookings, AI-driven backlog and expanding burn-in portfolio give it the edge over FormFactor for long-term growth.

After losing some value lately, a hammer chart pattern has been formed for Aehr Test Systems (AEHR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.